Interactive Video Lecture
Maximizing the Potential of Novel Therapies for Prostate Cancer
Release Date: August 17, 2021
Expiration Date: August 16, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
The treatment landscape for prostate cancer has become considerably more complex as new agents are approved and treatment strategies are now specialized for different disease settings. Navigating this complex clinical landscape requires a thorough knowledge of the disease, the evidence supporting recently approved treatment options, and an understanding of how to incorporate these agents safely into a plan of care. This activity provides a review of data informing numerous treatment strategies for nonmetastatic and metastatic castrate-resistant prostate cancer and for metastatic hormone-sensitive disease. Expert advice is offered via a case-based approach with guidance for selecting therapy based on patient and disease characteristics and strategies for managing therapy-related adverse events.
Format
Interactive video lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Describe novel treatments for advanced prostate cancer
- Identify the appropriate use of novel agents for advanced prostate cancer
- Apply recommended strategies to manage adverse events in order to foster adherence to treatment
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Alicia Morgans, MD, MPH
- Genitourinary Medical Oncologist
- Medical Director, Survivorship Program
- Dana-Farber Cancer Institute
- Boston, Massachusetts
Corinne Williams, PA-C
- Physician Assistant
- Division of Hematology/Oncology
- Robert H. Lurie Comprehensive Cancer Center
- Northwestern University Feinberg School of Medicine
- Chicago, Illinois
- Immediate Past President
- Association of Physician Assistants in Oncology
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pfizer; AstraZeneca; Bristol-Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme; and Seagen Inc. formerly Seattle Genetics.
This activity is supported by educational grants from Astellas and Pfizer; AstraZeneca; Dendreon Pharmaceuticals LLC; Merck & Co., Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Morgans: consulting: AAA Pharmaceuticals, Astellas, AstraZeneca, Blue Earth, Bayer, Dendreon, Clovis, Janssen, Myovant, Myriad, Pfizer, Sanofi; research support: Bayer, Dendreon, Sanofi, Seattle Genetics.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7E